Philippines - English - FDA (Food And Drug Administration)

n/a; importer: khriz pharma trading inc.; distributor: khriz pharma trading inc. - ceftriaxone (as sodium) - powder for injection (iv) - 1 g

Philippines - English - FDA (Food And Drug Administration)

one pharma marketing inc.; distributor: one pharma marketing inc. - rebamipide - film-coated tablet - 100 mg

United States - English - NLM (National Library of Medicine)

cardinal health - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with its use (see warnings below), amiodarone hydrochloride tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. because of the life-threatening nature of

United States - English - NLM (National Library of Medicine)

american health packaging - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with its use (see warnings below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. - recurrent ventricular fibrillation. - recurrent hemodynamically unstable ventricular tachycardia. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory con

Philippines - English - FDA (Food And Drug Administration)

one pharma company, inc.; distributor: one pharma company, inc. - sodium hyaluronate - ophthalmic solution (drops) - 1 mg/ml

Philippines - English - FDA (Food And Drug Administration)

blue sky trading co., inc.; importer: none; distributor: none - zinc oxide - ointment - 0.2

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - because of its life-threatening side effects and the substantial management difficulties associated with its use (see warnings below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. - recurrent ventricular fibrillation. - recurrent hemodynamically unstable ventricular tachycardia. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: amb hk enteprises inc.; distributor: cyden medicale trading inc - co-amoxiclav - powder for oral suspension (raspberry flavor) - 457 mg/5 ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: amb hk enterprises inc; distributor: cyden medicale trading inc - co-amoxiclav - powder for oral suspension - 312.5 mg per 5 ml

Philippines - English - FDA (Food And Drug Administration)

aglobal care, inc.; distributor: aglobal care, inc. - sterile water for injection - none - none